Dyne Therapeutics reports larger-than-expected Q2 net loss per share

Overview

• U.S. neuromuscular drug developer's Q2 net loss per share was larger than analyst expectations

• RD and GA expenses rose on higher manufacturing, clinical costs and launch preparations

• Company completed $431 mln public offering; expects cash runway into Q2 2028

Outlook

• Dyne expects potential U.S. launch of z-rostudirsen in Q1 2027, pending FDA approval

• Company plans topline data for z-basivarsen ACHIEVE trial in Q1 2027

• Dyne projects cash runway into Q2 2028

Result Drivers

• HIGHER CLINICAL COSTS - Co said increased RD expenses were mainly due to higher manufacturing activity and clinical costs for z-rostudirsen and z-basivarsen

• LAUNCH PREPARATIONS - Co attributed higher GA expenses to increased costs in preparation for the potential launch of z-rostudirsen

Company press release: ID:nGNXbG6Ps4

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology medical research peer group is "buy"

• Wall Street's median 12-month price target for Dyne Therapeutics, Inc is $40.00, about 54.4% above its July 28 closing price of $25.90

Reuters Recommended Reads

• July 29 - FDA panel votes against Capricor's Duchenne heart disease therapy

• July 27 - Sarepta names former Abbvie president as CEO as Ingram retires

• July 29 - Viking Therapeutics reports Q2 milder-than-expected net loss as obesity trials advance

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)